Multicenter Postmarket Analysis of the Neuroform Atlas Stent for Stent-Assisted Coil Embolization of Intracranial Aneurysms
Jan‐Karl Burkhardt, Visish M. Srinivasan, Aditya Srivatsan, Felipe C. Albuquerque, Andrew F. Ducruet, Benjamin K Hendricks, Bradley A. Gross, Brian T. Jankowitz, Ajith J. Thomas, Christopher S. Ogilvy, Georgios Α. Maragkos, Alejandro Enríquez-Marulanda, R. Webster Crowley, Michael R. Levitt, Louis J. Kim, Christoph J. Griessenauer, Clemens M. Schirmer, Satish Dalal, Keaton Piper, Maxim Mokin, Ethan A. Winkler, Adib A. Abla, Cameron M. McDougall, Lee Birnbaum, Justin Mascitelli, Miguel Litao, Omar Tanweer, Howard A. Riina, Jeremiah N. Johnson, Stephen Chen, Peter Kan
Abstract
BACKGROUND AND PURPOSE: The Neuroform Atlas is a new microstent to assist coil embolization of intracranial aneurysms that recently gained FDA approval. We present a postmarket multicenter analysis of the Neuroform Atlas stent. MATERIALS AND METHODS: On the basis of retrospective chart review from 11 academic centers, we analyzed patients treated with the Neuroform Atlas after FDA exemption from January 2018 to June 2019. Clinical and radiologic parameters included patient demographics, aneurysm characteristics, stent parameters, complications, and outcomes at discharge and last follow-up. RESULTS: = .03). CONCLUSIONS: This multicenter analysis provides a real-world safety and efficacy profile for the treatment of intracranial aneurysms with the Neuroform Atlas stent.